SCHEMBL9892693

SCHEMBL9892693

CNC(=O)Cc1cc(C(F)(F)F)ccc1-c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.48
HTR2A P28223 1/20 0.43
SLC6A4 P31645 1/20 0.43
KCNH2 Q12809 1/20 0.43
ANO1 Q5XXA6 1/20 0.43
KDM1A O60341 1/20 0.42
LMNA P02545 1/20 0.42
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42
APH1A Q96BI3 1/20 0.42
PSENEN Q9NZ42 1/20 0.42
CNR2 P34972 1/20 0.41
GCGR P47871 4/20 0.41
TACR1 P25103 2/20 0.41
TACR2 P21452 1/20 0.41
DHODH Q02127 1/20 0.40
CCR1 P32246 1/20 0.40
CSNK1D P48730 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9890782 0.92 PSEN1 (0.45) PTGDR2LMNAPSEN1PSEN2APH1B
SCHEMBL9892679 0.87 PTGDR2 (0.47) PTGDR2PSEN1PSEN2APH1BNCSTN
SCHEMBL9892659 0.84 PTGDR2 (0.59) PTGDR2ANO1KDM1APSEN1PSEN2
SCHEMBL9890777 0.83 PSEN1 (0.46) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL9892683 0.83 PTGDR2 (0.51) PTGDR2ANO1KDM1APSEN1PSEN2
SCHEMBL9890773 0.83 CNR1 (0.44) HTR2ASLC6A4KCNH2ANO1LMNA
SCHEMBL9890779 0.81 ALDH1A1 (0.44) PTGDR2SLC6A4ANO1CNR2
SCHEMBL9890771 0.80 SHMT1 (0.47) ANO1GCGR
SCHEMBL2395131 0.79 KCNJ5 (0.49) SLC6A4LMNAPSEN1PSEN2APH1B
SCHEMBL9890728 0.77 FFAR1 (0.46) PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885HTR2A 600/4885SLC6A4 932/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 PTGDR2 1062/4885HTR2A 600/4885SLC6A4 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.